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Abstract: Human G-protein coupled receptors (GPCRs) are important targets for pharmaceutical
intervention against neurological diseases. Here, we use molecular simulation to investigate the
key step in ligand recognition governed by the extracellular domains in the neuronal adenosine
receptor type 2A (hA2AR), a target for neuroprotective compounds. The ligand is the high-affinity
antagonist (4-(2-(7-amino-2-(furan-2-yl)-[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-ylamino)ethyl)phenol),
embedded in a neuronal membrane mimic environment. Free energy calculations, based on
well-tempered metadynamics, reproduce the experimentally measured binding affinity. The results
are consistent with the available mutagenesis studies. The calculations identify a vestibular binding
site, where lipids molecules can actively participate to stabilize ligand binding. Bioinformatic
analyses suggest that such vestibular binding site and, in particular, the second extracellular loop,
might drive the ligand toward the orthosteric binding pocket, possibly by allosteric modulation.
Taken together, these findings point to a fundamental role of the interaction between extracellular
loops and membrane lipids for ligands’ molecular recognition and ligand design in hA2AR.
Keywords: adenosine receptor; metadynamics; extracellular loops; allosterism
1. Introduction
The human adenosine receptor type 2A (hA2AR, Figure 1) belongs to the human G protein-coupled
receptors (GPCRs) [1], the largest membrane receptor family [2], essential for cell trafficking [3].
A2AR, highly localized in the striatum of the brain [4], is considered a promising drug target for
Molecules 2018, 23, 2616; doi:10.3390/molecules23102616 www.mdpi.com/journal/molecules
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combating Parkinson’s disease [5]. As in the other GPCRs, A2AR folds in seven transmembrane
helices (H1 to H7), connected by three extracellular loops (ECL1 to ECL3) and three intracellular
loops (ICL1 to ICL3). The N-terminus is extracellular, while the C-terminus is intracellular (Figure 1).
Agonists and antagonists bind to the receptors’ orthosteric binding site (OBS), mostly from the
extracellular space. The OBS is well extended into the hydrophobic core of the transmembrane
bundles [6]. Agonist binding causes conformational changes of the receptor that ultimately lead to a
variety of downstream processes.
A key role for ECLs in the early stages of molecular recognition of a variety of GPCRs is currently
emerging [7]. They may influence ligand binding kinetics [8], serve as flexible gatekeepers along the
ligand binding pathway [7,9], and act as selectivity filters against ligand subtypes [10]. ECLs may also























on  a  small  number  of  collective  variables  (CVs)  [18,19]. Not  only  can metadynamics  accurately 
predict the absolute ligand binding free energy [17], but it also reconstructs a multi‐dimensional, CV‐
dependent  free  energy  surface,  from which  receptor  interaction  sites  and  ligand  binding  poses, 
corresponding  to  local  free energy minima,  can be  identified. We  focus on  the human adenosine 






correctly  reproduce  ligand/receptor  interactions  [27].  In  particular,  the  inclusion  of  a  realistic 
membrane environment turned out to impact on the description of the molecular recognition events 
[27–29], here and in other GPCRs [30–32]. 
Figure 1. Snake view of hA2AR sequence, generated by GPCRDB [16]. Residues are colored di ferently
depending on their polarity.
ence, a detailed understanding of ECLs’ role for 2 R/ligand interactions may provide ne
opportunities for designing novel ligands targeting neurodegenerative diseases [5]. ere e explore
that role through ell-te pered etadyna ics [17,18]. This is a si ulation ethod that accelerates
the sa pling of specific degrees of freedo by adding a history-dependent potential ter that acts
on a s all nu ber of collective variables (CVs) [18,19]. Not only can etadyna ics accurately
predict the absolute ligand binding free energy [17], but it also reconstructs a multi-dimensional,
CV-dependent free energy surface, from which receptor interaction sites and ligand binding poses,
corresponding to local free energy ini a, can be identified. e focus on the hu an adenosine
receptor type 2 , in co plex ith its high-affinity antagonist Z ((4-(2-(7-a ino-2-(furan-2-yl)-
[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-ylamino)ethyl)phenol) or ZM241385, Figure 2) [20]. The syste
appears to be suitable for this research for several reasons. First, the structural deter inants of the
co plex are ell kno n [21–25]. Next, a comparison with biophysical and computational studies [26]
allowed us to establish the accuracy of our predictions. Finally, our computational setup—in particular
the modeling of the membrane and the choice of the force field—was shown to be able to correctly
reproduce ligand/receptor interactions [27]. In particular, the inclusion of a realistic membrane
environment turned out to impact on the description of the molecular recognition events [27–29],
here and in other GPCRs [30–32].


























Figure 3. Free‐energy  surface associated with ZMA/hA2AR  interactions, as a  function of collective 
variables,  CV1—a measure  of  ligand‐OBS  distance  and CV2—a measure  of  the  E169ECL2–H2647.29 
distance. The  figure shows  the minima associated with  the  ligand  located  in  the OBS A–C,  in  the 
vestibular binding site D in the salt bridge E and in a solvent‐exposed moiety of the ECL2 F. In the 
Figure 2. ZMA chemical structure, drawn with Maestro [33].
2. Results
We performed well-tempered metadynamics simulations [17,18] to investigate the role of ECLs in
ligand binding by reconstructing the free energy landscape of ZMA from the extracellular space to
its fully bound form to the receptor (see S ction 4 and Section S1 of the Supplementary Mate ials for
fur her details). The free en rgy is calculated as a function of two apt collective variables (Figu e 3).
The first (CV1) has alr ady b en used to describe lig nd binding/unbinding processes n GPCRs [19].
It is the di ance between the cent rs of mass (COMs) of ZMA a the Cα atoms of the transmembrane
helical bundles of hA2AR along the membrane’s normal axis. The second (CV2) takes into account the
distance betwe n H2647.29 and E169ECL2 at the entrance of the orth steric binding site (OBS) of hA2AR.
It is the distance between he Cα atom of E169ECL2 and the Cα atom of and H2647.29. These two
residues can indeed form a s lt bridge (see Section S2 and Table S1), which acts s a “gate” regulating
t en ranc of the ligand into the binding cavity [25,26]. The formation of this salt bridge is important
for the li and bindi g process [25,26]. Consiste tly, muta ions of the residues in Ala and Gln impact
the kinetics of unbindi g [26]. During the 3 0-ns simula ion, one cholesterol molecule b ds to the









for further details). The fre energy is calcu a ed as a function of two apt collective variables (Figure 
3). The first (CV1) has already been used to describe ligand binding/unbinding processes in GPCRs 















Figure 3. Free‐energy  surface associated with ZMA/hA2AR  interactions, as a  function of collective 
variables,  CV1—a measure  of  ligand‐OBS  distance  and CV2—a measure  of  the  E169ECL2–H2647.29 
distance. The  figure shows  the minima associated with  the  ligand  located  in  the OBS A–C,  in  the 
vestibular binding site D in the salt bridge E and in a solvent‐exposed moiety of the ECL2 F. In the 
Figure 3. Free-energy surface associated with ZMA/hA R interactions, as a function of collective
variables, CV1 a measure of ligand-OBS distance and CV2—a measure of the E169ECL2–H2647.29
distance. The figure shows the minima associated with the ligand located in the OBS A–C, in the
vestibular binding site D in the salt bridge E and in a solvent-exposed moiety of the ECL2 F. In the OBS,
the free energy in B and C are higher than that in A by 10.0 and 14.6 kJ/mol, respectively. G indicates
the unbound state.
The ligand bound to OBS in m nimum A (Figure 3) rep esent the subs ate with the largest
Boltzmann population, followed by minima B and C. However, the ligand turns out to also bind to an
external or “vestibular” binding site (VBS), in a significant populated min mum (D). D is form d not
only by helices’ residues but also by ECL1 and ECL2 re idues along with lipid molecules. ECL2 might
play an additional role in retrieving the ligand (F in Figure 3).
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2.1. The Orthosteric Binding Site
The ensemble of conformations forming A correspond to the OBS in the X-ray structures (Figure 4).
The free energy difference between A and the unbound state G is −79.5 kJ (see Section 4 and
Appendix A for a definition of G). The standard state free energy (∆G0) is calculated by taking into
account: (i) The residual binding free energy on passing from the unbound state G to isolated ligand
and receptor (∆GElec), this is estimated by solving the nonlinear Poisson-Boltzmann equation [34] and
(ii) The concentration of the protein in our simulation box (see Section 4). The calculated binding
free energy without ∆GElec is 62.3 kJ/mol, with the correction is −58.2 ± 3.3 kJ/mol. This compares
well with the experimental values found in the literature (Kd = 1.9 nM, ∆G0 = −54.4 kJ/mol) [21]
and that measured here (Kd = 0.8 nM, ∆G0 = −54.0 kJ/mol, see lower panel of Figure 4). The ligand
assumes an extended conformation similar to the ones present in other X-ray structures (Figure S1)
with a Root Main Square Deviation (RMSD) lower than 0.24 nm of the Cα residues in the binding site
(Figure S2). However, (i) the ligand’s bicyclic ring moiety flips by around 60 degrees relative to the
initial binding pose; (ii) the ZMA’s furan ring moiety stretches towards H1 and H2, while it interacts
with N2536.55 in this and other X-ray structures of the complex (see Figure S1). E169ECL2–H2647.29 salt
bridge is present for 90% of the structures belonging to A. Consistently, this salt bridge is present in
most PDB structures of hA2AR/ZMA complex (3EML [22], 4EIY [23], 3VG9 [24], 3VGA [24], 5UI7 [25],
5K2A/B/C/D [35], 5UVI [36], 5JTB [37], 5VRA [38], 6AQF [39] among others) except two (3PWH [21],
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Figure 4. Lowest energy binding pose of ZMA in the orthosteric binding site (OBS, minimum
A in Figure 3) in 3D (A) and 2D (B) representation. In (A) the protein backbone is render as
cartoon, ZMA is shown as a green licorice, residues interacting with ZMA are shown as gray lines.
The E16 ECL2-H2647.29 salt bridge is shown in cyan licorice. Hydrogen, oxygen, and nitrogen atoms
are specifically colored in white, red, and light blue, respectively. (B) 2D scheme of these binding pose
in (A). Saturation binding assay result (C) and competition binding assay result (D) of ZMA/hA2AR
complex as performed in this work. The other two binding poses of ZMA in B and C minima are
shown in Figure S3.
Minima B and C are higher in free energy by 10.0 kJ/mol and 14.6 kJ/mol. Here, the protein
residues are less packed around the ligand: The volume of the OBS cavity increases from A to B and
from B to C (0.38 nm3, 0.42 nm3, 0.45 nm3, for A, B, and C, respectively; see Table S2). The bicyclic
core of ZMA in binding poses in B and C is more deeply extended into the OBS of hA2AR than in state
A (see Figures S3 and S4). Interestingly, the E169ECL2–H2647.29 salt bridge interaction is formed in B
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but absent in C (99% and 2% of occurrence, respectively), as the Cα-Cα distance between E169ECL2
and H2647.29 increases from 0.6 nm to 1.3 nm. This indicates that the E169ECL2–H2647.29 salt bridge
interaction is affected by ligand binding in the OBS, as previously noted by Guo et al. [26].
2.2. Role of ECLs in Molecular Recognition
Minimum D is higher in free energy than A by approximately two times kBT (≈4 kJ/mol). It is
associated with two “vestibular” binding sites (VBS and VBS’ hereafter) located on the extracellular
surface of the receptor at opposite sides of ECL2. Only the minimum associated with VBS is
significantly populated (90% of the structures in D) and hence discussed here. Loops ECL1 and
ECL2 form the VBS along with the extracellular ends of helices H1, H2, H7, and one lipid molecule
(Figure 5). Lipids periodically find their way to that area and when the ligand is in the vestibular
binding pocket, they establish water-mediated interactions. Two of the residues involved in ZMA
binding, S672.65 and L2677.32, in the VBS, if mutated, increase the residence time of ZMA for hA2AR by
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conservation), M2707.35 (50% conservation), Y2717.36 (75% conservation) across the human adenosine 
receptor subtypes. Similar  trend of conservation of  these residues  in A2AR across species  is  found 
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than  A), we  suggest  here  it might  play  a  role  for  ZMA’s  binding  to  the  receptor. Mutagenesis 
experiments found K153ECL2A mutation significantly decreased the dissociation rate of ZMA for hA2AR 
[26]. Mutations of two glutamic residues (E151ECL2 and E161ECL2) which are also  located on the same 
Figure 5. ZMA binding poses in the minimum D of Figure 3 is shown in the (A–C) panels as 3D,
surface, and 2D representation, respectively. In (A) the protein backbone is rendered as a cartoon,
ZMA and POPC molecules are shown as a green and yellow licorice, respectively, residues interacting
with ZMA are shown as gray lines. Hydrogen, oxygen and nitrogen atoms are specifically colored in
white, red and light blue, respectively. In (B) the solid protein surface, based on Van der Waal atom
radii, is shown in orange.
Among the residues that comprise the VBS, those located on ECL2, e.g., N154ECL2, H155ECL2 and
A165ECL2, and H7, e.g., L2677.32, are not conserved across the human adenosine receptor subfamilies
(Table S3). On the other hand, most of the residues located on the head of the remaining helices
are better conserved, including Y91.35 (100% conservation), E131.39 (100% conservation), S672.65
(75% conservation), M2707.35 (50% conservation), Y2717.36 (75% conservation) across the human
adenosine receptor subtypes. Similar trend of conservation of these residues in A2AR across species is
found (Table S3).
In the minimum F, ZMA interacts with a solvent-exposed motif of ECL2 (Figure 6):
its 4-hydroxyphenyl moiety forms a hydrogen bond with E161ECL2, a water-mediated hydrogen
bond with K150ECL2 and hydrophobic interactions with G152ECL2, K153ECL2, N154ECL2, H155ECL2
alkyl groups.
Although this minimum is not significantly populated (F is −20.92 kJ/mol higher in free energy
than A), we suggest here it might play a role for ZMA’s binding to the receptor. Mutagenesis
experiments found K153ECL2A mutation significantly decreased the dissociation rate of ZMA for
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hA2AR [26]. Mutations of two glutamic residues (E151ECL2 and E161ECL2) which are also located
on the same solvent-exposed region of ECL2 have been shown to exert strong effects on ligand
binding affinity [41]. The residues composing this solvent-exposed motif (K150–E161) are overall
non-conserved (Figure S5) across the four human adenosine subfamilies. However, the conservation of




















suggested  to  be  responsible  for  the  selective  binding  of  a novel  bitopic  antagonist  against  other 
adenosine receptor subtypes [42]. 
The  E169ECL2–H2647.29  salt  bridge  is  moderately  conserved  across  human  adenosine  receptor 
subfamily members (see Section S3). Residues located in the lower region of the OBS are generally more 
conserved than residues located in the upper part of the binding pocket [43]. The first have been suggested 








representation, respectively.  In  (A)  the protein backbone  is render as cartoon, ZMA  is shown as a 
green  licorice,  residues  interacting with ZMA  are  shown  as gray  lines. The E169ECL2  and H2647.29 
Figure 6. ZMA binding poses in the minimum F of Figure 1 are shown in the (A,B) panels, as 3D and
2D representation, respectively. In (A) the protein backbone is render as cartoon, ZMA is shown as a
green licorice, residues interacting with ZMA are shown as gray lines. Hydrogen, oxygen, and nitrogen
atoms are specifically colored in white, red, and light blue, respectively.
2.3. An Access Control Binding Site
In E, ZMA interferes with the E169ECL2–H2647.29 salt bridge (Figure 7) by H-bonding E169ECL2.
The ligand additionally forms hydrophobic interactions with I662.64 and water-mediated hydrogen
bonding interaction with S672.65, as in [26]. Consistently, H264ECL2A and E169ECL2Q variants [26]
impact on a ligand’s dissociation rate, as do I662.64A and S672.65A variants on a ligand’s residence
time in A2AR [26]. Interestingly, most of the residues involved in this binding site, specifically I662.64,
S672.65, Y91.35, M2707.35, and Y2717.36, correspond to a recently identified cryptic allosteric pocket [42].
The latter was suggested to be responsible for the selective binding of a novel bitopic antagonist against
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representation, respectively.  In  (A)  the protein backbone  is render as cartoon, ZMA  is shown as a 
green  licorice,  residues  interacting with ZMA  are  shown  as gray  lines. The E169ECL2  and H2647.29 
Figure 7. ZMA binding poses in the minimum E of Figure 3 is shown in (A,B) panels, as 3D and 2D
representation, respectively. In (A) the protein backbone is render as cartoon, ZMA is shown as a green
licorice, residues interacting with ZMA are shown as gray lines. The E169ECL2 and H2647.29 residues
are shown in cyan licorice. Hydrogen, oxygen and nitrogen atoms are specifically colored in white,
red and light blue, respectively.
The E169ECL2–H2647.29 salt bridge is moderately conserved across human adenosine receptor
subfamily members (see Section S3). Residues located in the lower region of the OBS are generally
more conserved than residues located in the upper part of the binding pocket [43]. The first have
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been suggested to play a role for ligand affinity, the second for ligand specificity [43]. Here we
demonstrate that the E169ECL2–H2647.29 salt bridge is better conserved in A1Rs and A2ARs than A2BRs
and A3Rs (see Section S3). Granier et al. [10] has suggested that diversity in amino acid composition
in the outer part the binding pocket may contribute to selection filter for larger ligands. Given these,
we speculate that the gated access control site present at the binding pocket entrance of hA2AR, may be
one important structural property that can selectively modulate ligands’ entering the OBS of adenosine
receptor subtypes.
In conclusion of this section, let us analyze some common trends across the identified binding sites.
As ZMA moves from the solvent-exposed minimum F to the membrane-facing vestibular minimum D,
the number of water molecules decreases and the volume of OBS is the smallest (Table S2 number of
water molecules around the ligand decreases from 33 (F) to 21 (D) while the volume of OBS increases
from 0.33 nm3 to 0.34 nm3 (see Table S2). In minimum E and, even more in OBS, the number of water
molecules decreases and OBS volume increases (Table S2). These trends are consistent with those
uncovered in a microsecond-scale MD study [14] of the family A GPCR sphingosine-1-phosphate
receptor [44].
2.4. Allosterism
We next asked ourselves whether the VBS and ECLs might act as allosteric sites for OBS. To address
this issue, we focused on coevolving residues (residue pairs that are mutated in concert more frequently
than random genetic events) between receptor binding sites and other protein regions [45–47]. Indeed,
the latter are likely to play a role in the allosteric modulation of ligand binding [48].
The presence of allosterism is then identified by the so-called residue-paired coevolution score
(PCS) [46]. The score ranges from 0 (no covariation) to 0.5 (moderate covariation) and 1 (complete
covariation) [46]. In VBS, E131.39 and Y91.35 show moderate coevolutionary relation (PCS > 0.4) with
residues located in the OBS, including V843.32, L853.33, N1815.42 and I2747.39 and H2787.43 (Figure 8 and
Table S4). Also, G69ECL1 show moderate coevolutionary relation (PCS > 0.4) with H2787.43. Moreover,
we find that M1775.38, I2747.39 and H2787.43 in the OBS [49] coevolve with G142ECL2 and W143ECL2
belonging to VBS’ (PCS 0.4–0.6). Interestingly, these two residues also coevolve with E131.39 in VBS.
Inspection of the structure allowed identifying a possible network of interactions connecting VBS and
ECLs with OBS. E13 was shown to play a role in the stabilization of the UK432097 agonist and has
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Figure 8. Coevolution relationships bet ee a i aci s of the relevant regions studied in this article
(Table S4) based on Coeviz web server analyses [46].
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Hence, we conclude that ECL2 and VBS residues might be allosterically coupled with OBS. PCS
analysis of the available crystallized 27 human GPCRs with OBS-bound ligand complex structures
(subclasses A, B, C, and F) shows that, in the majority of them (22 structures), extracellular loops
residues coevolve with OBS ones (Table S5). A section is offered in the Supplementary Materials on
the sodium allosteric binding site (Section S4).
3. Discussion
Our metadynamics simulations have provided the free energy landscape of ZMA binding to
hA2AR, embedded in a solvated neuronal-like membrane environment. Our calculations are consistent
with the available experimental (i) and simulated (ii) data: (i) the predicted Kd is in agreement with that
derived by measurements available in the literature [21] and performed in this work. (ii) The free-energy
profile features a ‘multi-minima’ landscape, consistent with a multi-step dissociation process suggested
by previous temperature accelerated molecular dynamics simulation [26]. In particular, the residues
interacting with the ligand in [26] are the same ones in our minima.
The ligand is located in the OBS as in X-ray structure [21] (minimum A in Figure 4), but it slightly
differs in the orientation of its bicyclic ring. This might be ascribed, at least in part, to the dramatic
differences in the protein environment. Indeed, the environment changes from a detergent micelle of
the X-ray structure [21], to a membrane-mimicking environment, rich in cholesterol, in the MD [27,51].
Notably, cholesterol binds to a pocket located between helices H1 and H2 (see Figure 5 in [27]). This may
affect ligand binding poses (via an allosteric mechanism [27]) and affinity [30] in GPCRs.
Our metadynamics simulations further reveal the existence of significantly populated states
(minima B, C and E), where ZMA interferes with the E169ECL2–H2647.29 salt bridge located between
ECL2 and ECL3 of hA2AR. In minima B and C, the ligand is still in the OBS but in B, the phenol
moiety of ZMA form a hydrogen bond with E169ECL2, possibly weakening the electrostatic strength
of the salt bridge, while in C the phenol moiety is exposed toward the solvent and the salt bridge is
broken. Notably, despite the fact that the geometrical position of ZMA is very similar (see Figure S4),
the free energy increases on passing from B to C with respect to A, pointing toward a key role of such
salt bridge in controlling the dissociation kinetics of ligands, as also suggested in [8]. Accordingly,
H2647.29A and E169ECL2Q mutations impact on the ligand’s dissociation rate [26]. In E, ZMA is
located between the OBS and the VBS and, although the E169ECL2–H2647.29 is formed, its electrostatic
strength is possibly decreased by a hydrogen bond of the ligand’s triazin moiety with E169ECL2. In this
binding site, ZMA also interacts directly with I662.64 and forms a water-mediated hydrogen bonding
interaction with S672.65. These residues, if mutated in alanine, I662.64A and S672.65A, impact on the
ligand’s residence time in A2AR [26].
The E169ECL2–H2647.29 salt bridge therefore seems to act as a “narrowing gate”, similar to what
was observed in human GPCR β2 adrenergic receptor. Here, the D192ECL2–K3057.32 salt bridge acts as
a gate and the salt bridge is located at the entrance of the OBS of this receptor, deeply buried in the
transmembrane region [11,52].
In addition to these minima, the extracellular loops ECL1, ECL2, as well as the heads of helices H1,
H2, H7, contribute to the formation of a previously unnoticed, significantly populated vestibular binding
site (VBS) accommodating the ligand (minimum D). Consistently, mutating S672.65 and L2677.32, two VBS
residues, increase the residence time of ZMA for hA2AR by 1.5–2.3-fold, while showing negligible
influence on the ligand binding affinity [26]. The role of some residues in ECL1 ECL2 of hA2A in ligand
binding affinity was already shown elsewhere [53], and the discovery that ECL2 forms the VBS is in line
with several studies on other GPCRs [11–13,15]. However, we suggest here that such VBS is not transient
but is actually significantly populated. Interestingly, the recently resolved structure of hA2AR in complex
with 5-amino-N-[(2-methoxyphenyl)methyl]-2-(3-methylphenyl)-2H-1,2,3-triazole-4-carboximidamide
(Cmpd-1, hereafter) identified one potential allosteric pocket [42] that is located in the helical part of the
VBS, as the one identified from our metadynamics simulation. Specifically, the site accommodating the
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methoxyphenyl group of Cmpd-1 consists of Y91.35, A632.61, I662.64, S672.65, L2677.32, M2707.35, Y2717.36
and I2747.39, five of which are located in the helical part of the VBS (see Figure 5).
A further interesting feature of our identified VBS, is that a lipid molecule contributes to the
stabilization of the ligand binding. A key role of lipids for ligand binding has been already pointed out
in other studies (see, for instance, [54,55]). The lipid bilayer was found to form the determinant entry
pathway along which the ligand gains access to GPCRs [56] and even form a “membrane vestibule”
that controls ligand binding kinetics [14]. Lipid composition in membrane could also modulate stability
of specific ligand binding pose [27,28]. Therefore, altered lipid composition in the neuronal membrane
could affect ligand binding. This, in turn, could alter the function of the receptor [57,58].
ECL2 forms a third binding site on the solvent-exposed region of the receptor, topographically
distinct from the VBS (minimum F). The existence of the site might be consistent with mutagenesis
experiments [26,41], since mutations of residues E151ECL2, K153ECL2, and E161ECL2, which are found
to directly interact with ZMA in our simulations, significantly influence ligand binding affinity or
dissociation speed. At the speculative level, we suggest that ECL2 might function as a ‘fishing’ moiety
for the ligand in the extracellular compartment, redirecting it toward the VBS, consistent with the fact
that the volume of the OBS increases upon ligand binding from ECL2 to the OBS.
Specific residues belonging to VBS or located in the ECLs, turn out to co-evolve with residues
in the OBS, suggesting an allosteric pathway connecting the extracellular domains of the receptor to
OBS (Figure 8). The pathway might impact on ligand binding. A similar conclusion was reached for
another GPCR, the dopamine D2 receptor. For the latter, coevolved residues pairs show functional
coupling in controlling responses to dopamine [59].
We close this section by analyzing major limitations of this work. First, experimental evidence
indicates that hA2AR can form homo- and/or hetero-assemblies of two or more monomers [60,61]. It is
expected that oligomeric order and architecture of the supramolecular assembly, not considered here,
may affect ligand binding [62]. Second, the prediction of energetics and binding poses is determined by
a priori choice of a set of CVs [19,63]. In this case, this issue might be alleviated by the fact that a wide
range of optimal CVs are available to describe ligand binding to a GPCR [19]. Third, the calculated
absolute ligand binding free energy might contain a significant source of inaccuracy from the use of
necessarily approximate force fields [64] as well as nonlinear Poisson–Boltzmann calculations [34].
Fourth, the level of theory we employed inherently neglect the electronic degrees of freedom, that
might be relevant for ligand binding. However, in this case no covalent binding occurs and therefore
the polarization effects are negligible. Fifth, other components of cellular membrane, such as
polyunsaturated chains and sphingolipids, have not been included in our membrane model [27].
The content of these is far less than cholesterol, however, also these biomolecules might impact on
GPCRs function [65]. Finally, the sodium ion, recently discovered in the high-resolution structure of
hA2AR [66], was not considered here. The consistency with experiments makes us suggest that these
issues do not affect substantially the main predictions of the paper, namely the contribution of ECL2 to
two significantly populated binding sites other than the OBS, along with the key role of lipids for the
molecular recognition process.
4. Materials and Methods
4.1. System Preparation and MD Simulations
We have shown elsewhere that the conformation of the hA2AR is affected by membrane
composition [27]. One of the main players in membrane-driven modulation of hA2AR is cholesterol,
that specifically binds in a cleft between H1 and H2 and can allosterically affect the shape of the
orthosteric binding site (OBS). Despite the fact that in cellular membranes, cholesterol content
varies from 33% to 50% [67], unfortunately, cholesterol-driven allosteric effects are not captured
in X-ray structures since artificial detergent-based environment or solubilizing antibodies are used [68].
In an effort to model hA2AR in a membrane environment mimicking the real cellular membrane,
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we embedded the receptor in a membrane of 42% POPC, 34% POPE and 25% of cholesterol molecules,
mimicking the ratio among the three components in human cellular plasma membranes [69]). In our
previous study, we showed that cholesterol affects the receptor structure, in the equilibrated part of
the simulation. Therefore, to include the cholesterol-driven allosteric effects in the model, we used
as starting conformation for hA2AR the last snapshot of the our previous 800-ns MD simulation of
cholesterol-bound hA2AR with caffeine, embedded in a membrane with the same composition [27].
An educated guess of the ZMA binding pose in the cholesterol-bound hA2AR was obtained
by superimposing ZMA via Pymol [70] software in the binding cavity, using as a template the
configuration that ZMA has in the 3PWH X-ray structure [21]. Structural comparison (Figure S1) and
Root Mean Square Deviation (RMSD) (Figure S2) across most of the X-ray structures of ZMA available
so far in complex with hA2AR, is offered in the Supplementary Materials.
The protonation state of histidine residues, and in particular of H264 involved in forming the
salt bridge with E169, was evaluated by PROPKA [71] and cross-checked within available hA2AR
crystal structures (see Section S1). The AMBER99SB-ILDN force fields [72], the Slipids [73,74] and
the TIP3P [75] force fields were used for the protein and ions, the lipids, and the water molecules
respectively. The General Amber force field (GAFF) parameters [76] were used for ZMA, along with the
RESP atomic charge using Gaussian 09 [77] with the HF-6-31G* basis set [78,79]. MD simulations were
performed using Gromacs v4.5.5 package [80]. The total system is a 14.3 nm × 10.8 nm × 9.6 nm box,
including 248 POPC lipids, 204 POPE lipids, and 141 cholesterol molecules. The total number of atoms
in the system is 151,850. The computational protocols utilized in the previous study [27] was applied
here for the MD simulation of ZMA/hA2AR complex. Specifically, MD simulation was conducted in
the NPT ensemble (constant pressure and temperature) under periodic boundary conditions. Constant
temperature and pressure conditions were achieved via independently coupling protein, lipids, solvent
and ions to Nosè-Hoover thermostat [81] at 310 K and Andersen-Parrinello-Rahman Barostat [82] at
1 atm. The Particle Mesh Ewald method [83] was used to treat the long-range electrostatic interaction
with a real space cutoff of 1.2 nm. A 1.2-nm cutoff was used for the short-range non-bonded interaction.
A time step of 2 fs was set. The LINCS algorithm [84] was applied to constrain all bonds involving
hydrogen atoms. The final system was equilibrated for 20 ns under constant pressure and temperature
(NPT ensemble) before metadynamics simulation.
4.2. Metadynamics Simulations
The well-tempered metadynamics approach [17,18], an enhanced sampling algorithm within the
framework of classical MD, was applied together with the computational protocol above to delineate
the free energy profile for the binding of ZMA to hA2AR within the solvated neuronal-like membrane
model (see Section S1 for further details on the methods). The deposition rate of the Gaussian bias
terms was set to 1 ps and the initial height to 1.0 kJ/mol, with a bias factor of 15. To obtain the
free energy profile of ZMA binding to hA2AR, we used two different collective variables, termed
here CV1 and CV2 [19]. Specifically, CV1 was defined as the distance between the center of mass
(COM) of ZMA and COM of Cα atoms of the transmembrane helical bundles of hA2AR along the
membrane normal (Z-axis). CV2 corresponded to the distance between Cα atoms of H264 and E169.
Gaussian widths of 0.05 nm were selected for CV1 and CV2, respectively, based on inspection of
the initial dynamics of the system during equilibration. To restrict the sampling of conformational
states in which the ligand was in contact with the protein, lower and upper limits of 1.5 nm and
3.8 nm, respectively, for the values of CV1 were enforced using steep harmonic potentials with an
elastic constant of 250 kJ/nm2. Besides, one unbiased CV3 representing the XY component of the
distance between the COM of ligand and the COM of Cα atoms of the transmembrane helical bundles
of hA2AR was enforced below 1.2 nm so that the ligand would not diffuse to solvent regions that
are far away from the receptor. All calculations used the Gromacs 4.5.5 program with the Plumed
1.3 plugin [85]. The unbinding free-energy was calculated as in [86–88]. The contribution to the
free energy of binding from the metadynamics ∆GMetaD was calculated as the free energy difference
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between the local minimum A (CV1 = [1.58 nm, 1.75 nm], CV2 = [0.82 nm, 0.91 nm]) and the unbound
state G (CV1 = [4.40 nm, 4.50 nm], CV2 = [1.10 nm, 1.30 nm]); see Appendix A for further details
of G definition. The contribution for CV1 > 4.5 nm (∆GElec) was estimated through the nonlinear
Poisson-Boltzmann equation by using APBS 1.4 program [34]. The setup for ∆GElec calculation is the
following: The interior dielectric constant of the hA2AR was set to 4 and that of the solvents to 80.
The concentration of sodium and chloride ions are set to 0.15 M. The total calculated value for the free
energy of binding was obtained as ∆G = ∆GMetaD + ∆GElec. The standard-state free energy of binding





. R is the molar constant, [P] is the concentration of
the protein in our simulation box, and [P]0 = 1 M is the standard-state concentration [88]. ∆G0 was
compared with the experimental binding free energies through the relationship ∆G0 = RTlnkeq,
where keq is the experimental equilibrium constant.
Volume analysis of the OBS of hA2AR was performed with trj_cavity 2.1 [89]. The residues
comprising the OBS of hA2AR are defined as those within 0.6 nm of ZMA in the X-ray structure
(PDBid:3PWH) [21]. Calculation of number of water molecules was performed with VMD [90].
The number of water molecules within 4 Å of ZMA is averaged over frames collected for each state.
Coevolution analysis was performed with the web-based tool CoeViz [46] integrated in the web server
POLYVIEW-2D [91].
4.3. Experimental Affinity Testing
4.3.1. Cell Culture
The cells were grown at 37 ◦C in 5% CO2/95% air adherently and kept in Ham’s F12 Nutrient
Mixture, containing penicillin (100 U/mL), 10% fetal bovine serum, Geneticin (G418, 0.2 mg/mL),
streptomycin (100 µg/mL), and L-glutamine (2 mM). Cells were split two or three times per week at a
ratio between 1:5 and 1:20. The culture medium was removed and the cells were washed with PBS
buffer (pH 7.4), scraped off, suspended in 1 mL PBS per dish, and stored at −80 ◦C, to prepare them
for binding assays.
Membrane preparation for radioligand binding experiments. The cell were prepared as in [92].
The frozen cell suspension was thawed and homogenized on ice (Ultra-Turrax, 1 × 30 s at full
speed). The homogenate was next centrifuged for 10 min (4 ◦C) at 600× g. The supernatant was then
centrifuged for 60 min at 50,000× g after that, the membrane pellet was suspended again in 50 mM
Tris/HCl buffer (pH 7.4) and frozen in liquid nitrogen at a protein concentration of 6 mg/mL. Finally,
it was stored at −80 ◦C. Protein estimation used a naphthol blue black photometric assay [93] after
solubilization in 15% NH4OH containing 2% SDS (w/v); human serum albumin served as a standard.
4.3.2. Experimental Binding Affinity
Binding experiments used membranes from CHO K1 cells stably expressing the human A2A
adenosine receptor. [3H]ZM 241385 (0.8 nM in competition experiments) as radioligand was used to
obtain dissociation constant of [3H]ZM 241385 and the inhibition constant of not tritiated ZM 241385.
Membrane homogenates with a protein content of 15 µg immobilized in a gel matrix were incubated
with the radioligands in a total volume of 1500 µL 50 mM Tris/HCl buffer pH 7.4. This method
produces the same results as conventional separation techniques and will be published in detail
elsewhere. After an incubation time of 70 min the immobilized membrane homogenates were washed
with water and transferred into scintillation cocktail (5 mL each, Ultima Gold, Perkin Elmer, Waltham,
MA, USA). Liquid scintillation counter (Beckman Coulter, Brea, CA, USA) was used to measure the
radioactivity of the samples (bound radioactivity). All binding data were calculated by non-linear
curve fitting with a computer-aided curve-fitting program (Prism version 4.0, GraphPad Software, Inc.,
La Jolla, CA, USA).
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5. Conclusions
Neuronal hA2ARs, like other human GPCRs, are important pharmaceutical targets [94].
Here, we have presented a metadynamics study of the interaction between the high-affinity ligand
ZMA and hA2AR, embedded in a solvated neuronal-like membrane environment. The calculations are
consistent with the available experimental data and point to a clear and important role of lipids and of
the second extracellular loop for ZMA’s molecular recognition process.
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bridge: conservation across A2Ars, Section S4: Sodium allosteric binding site, Table S1: H2647.29 protonation
state across hA2AR X-ray structures, Table S2: Ligand hydration (defined here as the number of water molecules
within 4 Å of ZMA) and OBS volume for free energy minima A, B, C, D, E and F, Table S3. Conservation of
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Author Contributions: Conceptualization, G.R., P.C., A.B., and B.N.; methodology and formal analysis R.C. and
A.G.; investigation, all data curation, R.C; writing—original draft preparation, R.C., P.C. and G.R.; writing—review
and editing, all; supervision, B.N., A.B., A.G., G.R. and P.C.; Resources P.C. and B.N.
Funding: The research leading to these results has received funding from the European Union Seventh Framework
Programme (FP7/2007-2013) under grant agreement No. 604102 (Human Brain Project) and from the European
Union Horizon 2020 Research and Innovation Programme under Grant Agreement No. 720270 (HBP SGA1).
Co-design project 6 (CDP6) is a recipient of the Human Brain Project SGA1 grant.
Acknowledgments: We have to express our appreciation to Dirk Bier of the Institute of Neuroscience and
Medicine at Forschungszentrum Jülich for conducting the binding assay experiments and sharing affinity data
with us. The authors also gratefully acknowledge the computing time provided by John von Neumann Institute
for Computing on the supercomputer JURECA at Jülich Supercomputer center.
Conflicts of Interest: The authors declare no conflict of interest.
Appendix A
The binding free energy depends on the difference between the free energy of fully bound state
GB and that of the unbound state (GU) in which ZMA is located at infinite distance from the receptor:
∆G = GU − GB
However, this calculation of GU is not possible given the necessarily finite size of the simulation
box. To circumvent this problem, let us rewrite ∆G as the sum of two contributions:
∆G = GU − GG + GG − GB = GWTM − ∆Gresidual
G is the relative minimum represented in Figure 3. GWTM is by far the largest contribution,
and it calculated by well-tempered metadynamics. Gresidual is well approximated by the free energy
associated with long-range electrostatic interactions with the protein (∆Gresidual ≈ ∆Gelectr). Indeed,
the ligand in G does not form direct H-bonds and/or hydrophobic contacts with the protein. It is at
about 0.8 nm from the protein atoms, separated by water molecules. Hence, it forms only long-range
electrostatic interactions with the membrane and the protein. However, the latter are vanishingly
small because the ligand is at least 2.5 nm from the membrane. In addition, we notice that in G the
conformational degrees of freedom of the ligand are not partially restricted. Hence, the entropic
contribution associated with these degrees of freedom is expected to be also vanishingly small.
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∆Gelectr is expected to be much smaller than ∆GWTM, as ∆Gelectr values lower than 2kBT have been
calculated for other ligand/protein interactions [88,95]. Indeed, a posteriori, ∆Gelectr, as calculated
using the APBS 1.4 program [34], turns out to be only 0.95 Kcal/mol. We conclude that the corrections
due to the finite size of the simulation box are small. In other words, the ligand in G interacts
very weakly with the protein. Hence, the errors in the calculations of this term are not expected to
dramatically affect the binding free energy.
References
1. Fredholm, B.B.; IJzerman, A.P.; Jacobson, K.A.; Klotz, K.N.; Linden, J. International Union of Pharmacology.
XXV. Nomenclature and classification of adenosine receptors. Pharmacol. Rev. 2001, 53, 527–552. [PubMed]
2. Kroeze, W.K.; Sheffler, D.J.; Roth, B.L. G-protein-coupled receptors at a glance. J. Cell Sci. 2003, 116, 4867–4869.
[CrossRef] [PubMed]
3. Schöneberg, T.; Schulz, A.; Biebermann, H.; Hermsdorf, T.; Römpler, H.; Sangkuhl, K. Mutant
G-protein-coupled receptors as a cause of human diseases. Pharmacol. Ther. 2004, 104, 173–206. [CrossRef]
[PubMed]
4. Fink, J.S.; Weaver, D.R.; Rivkees, S.A.; Peterfreund, R.A.; Pollack, A.E.; Adler, E.M.; Reppert, S.M. Molecular
cloning of the rat A2 adenosine receptor: Selective co-expression with D2 dopamine receptors in rat striatum.
Brain Res. Mol. Brain Res. 1992, 14, 186–195. [CrossRef]
5. Xu, K.; Bastia, E.; Schwarzschild, M. Therapeutic potential of adenosine A(2A) receptor antagonists in
Parkinson’s disease. Pharmacol. Ther. 2005, 105, 267–310. [CrossRef] [PubMed]
6. Gimpl, G. Interaction of G protein coupled receptors and cholesterol. Chem. Phys. Lipids 2016, 199, 61–73.
[CrossRef] [PubMed]
7. Peeters, M.C.; van Westen, G.J.P.; Li, Q.; IJzerman, A.P. Importance of the extracellular loops in G
protein-coupled receptors for ligand recognition and receptor activation. Trends Pharmacol. Sci. 2011, 32,
35–42. [CrossRef] [PubMed]
8. Katritch, V.; Cherezov, V.; Stevens, R.C. Structure-function of the G protein-coupled receptor superfamily.
Annu. Rev. Pharmacol. 2013, 53, 531–556. [CrossRef] [PubMed]
9. Avlani, V.A.; Gregory, K.J.; Morton, C.J.; Parker, M.W.; Sexton, P.M.; Christopoulos, A. Critical role for the
second extracellular loop in the binding of both orthosteric and allosteric G protein-coupled receptor ligands.
J. Biol. Chem. 2007, 282, 25677–25686. [CrossRef] [PubMed]
10. Granier, S.; Kobilka, B. A new era of GPCR structural and chemical biology. Nat. Chem. Biol. 2012, 8, 670–673.
[CrossRef] [PubMed]
11. Dror, R.O.; Pan, A.C.; Arlow, D.H.; Borhani, D.W.; Maragakis, P.; Shan, Y.; Xu, H.; Shaw, D.E. Pathway and
mechanism of drug binding to G-protein-coupled receptors. Proc. Natl. Acad. Sci. USA 2011, 108, 13118–13123.
[CrossRef] [PubMed]
12. Sandal, M.; Behrens, M.; Brockhoff, A.; Musiani, F.; Giorgetti, A.; Carloni, P.; Meyerhof, W. Evidence for a
transient additional ligand binding site in the TAS2R46 bitter taste receptor. J. Chem. Theory Comput. 2015, 11,
4439–4449. [CrossRef] [PubMed]
13. Kruse, A.C.; Hu, J.; Pan, A.C.; Arlow, D.H.; Rosenbaum, D.M.; Rosemond, E.; Green, H.F.; Liu, T.; Chae, P.S.;
Dror, R.O.; et al. Structure and dynamics of the M3 muscarinic acetylcholine receptor. Nature 2012, 482,
552–556. [CrossRef] [PubMed]
14. Stanley, N.; Pardo, L.; Fabritiis, G.D. The pathway of ligand entry from the membrane bilayer to a lipid G
protein-coupled receptor. Sci. Rep. 2016, 6, 22639. [CrossRef] [PubMed]
15. Provasi, D.; Bortolato, A.; Filizola, M. Exploring molecular mechanisms of ligand recognition by opioid
receptors with metadynamics. Biochemistry 2009, 48, 10020–10029. [CrossRef] [PubMed]
16. Horn, F.; Weare, J.; Beukers, M.W.; Horsch, S.; Bairoch, A.; Chen, W.; Edvardsen, O.; Campagne, F.; Vriend, G.
GPCRDB: An information system for G protein-coupled receptors. Nucleic Acids Res. 1998, 26, 275–279.
[CrossRef] [PubMed]
17. Barducci, A.; Bussi, G.; Parrinello, M. Well-tempered metadynamics: A smoothly converging and tunable
free-energy method. Phys. Rev. Lett. 2008, 100, 020603. [CrossRef] [PubMed]
18. Laio, A.; Parrinello, M. Escaping free-energy minima. Proc. Natl. Acad Sci. USA 2002, 99, 12562–12566.
[CrossRef] [PubMed]
Molecules 2018, 23, 2616 14 of 17
19. Schneider, S.; Provasi, D.; Filizola, M. The dynamic process of drug-GPCR binding at either orthosteric or
allosteric sites evaluated by metadynamics. Methods Mol. Biol. (Clifton, N.J.) 2015, 1335, 277–294. [CrossRef]
20. Poucher, S.M.; Keddie, J.R.; Singh, P.; Stoggall, S.M.; Caulkett, P.W.; Jones, G.; Coll, M.G. The in vitro
pharmacology of ZM 241385, a potent, non-xanthine A2a selective adenosine receptor antagonist. Br. J.
Pharmacol. 1995, 115, 1096–1102. [CrossRef] [PubMed]
21. Dore, A.S.; Robertson, N.; Errey, J.C.; Ng, I.; Hollenstein, K.; Tehan, B.; Hurrell, E.; Bennett, K.; Congreve, M.;
Magnani, F.; et al. Structure of the adenosine A(2A) receptor in complex with ZM241385 and the xanthines
XAC and caffeine. Structure 2011, 19, 1283–1293. [CrossRef] [PubMed]
22. Jaakola, V.P.; Griffith, M.T.; Hanson, M.A.; Cherezov, V.; Chien, E.Y.; Lane, J.R.; Ijzerman, A.P.; Stevens, R.C.
The 2.6 angstrom crystal structure of a human A2A adenosine receptor bound to an antagonist. Science 2008,
322, 1211–1217. [CrossRef] [PubMed]
23. Liu, W.; Chun, E.; Thompson, A.A.; Chubukov, P.; Xu, F.; Katritch, V.; Han, G.W.; Roth, C.B.; Heitman, L.H.;
IJzerman, A.P.; et al. Structural basis for allosteric regulation of GPCRs by sodium ions. Science 2012, 337,
232–236. [CrossRef] [PubMed]
24. Hino, T.; Arakawa, T.; Iwanari, H.; Yurugi-Kobayashi, T.; Ikeda-Suno, C.; Nakada-Nakura, Y.; Kusano-Arai, O.;
Weyand, S.; Shimamura, T.; Nomura, N.; et al. G-protein-coupled receptor inactivation by an allosteric
inverse-agonist antibody. Nature 2012, 482, 237–240. [CrossRef] [PubMed]
25. Segala, E.; Guo, D.; Cheng, R.K.; Bortolato, A.; Deflorian, F.; Doré, A.S.; Errey, J.C.; Heitman, L.H.;
IJzerman, A.P.; Marshall, F.H. Controlling the dissociation of ligands from the adenosine A2A receptor
through modulation of salt bridge strength. J. Med. Chem. 2016, 59, 6470–6479. [CrossRef] [PubMed]
26. Guo, D.; Pan, A.C.; Dror, R.O.; Mocking, T.; Liu, R.; Heitman, L.H.; Shaw, D.E.; IJzerman, A.P. Molecular
basis of ligand dissociation from the adenosine A2A receptor. Mol. Pharmacol. 2016, 89, 485–491. [CrossRef]
[PubMed]
27. Cao, R.Y.; Rossetti, G.; Bauer, A.; Carloni, P. Binding of the antagonist caffeine to the human adenosine
receptor hA(2A)R in nearly physiological conditions. PLoS ONE 2015, 10, e0126833. [CrossRef]
28. Grouleff, J.; Irudayam, S.J.; Skeby, K.K.; Schiott, B. The influence of cholesterol on membrane protein
structure, function, and dynamics studied by molecular dynamics simulations. Biochim. Biophys. Acta 2015,
1848, 1783–1795. [CrossRef] [PubMed]
29. Guixà-González, R.; Albasanz, J.L.; Rodriguez-Espigares, I.; Pastor, M.; Sanz, F.; Martí-Solano, M.; Manna, M.;
Martinez-Seara, H.; Hildebrand, P.W.; Martín, M. Membrane cholesterol access into a G-protein-coupled
receptor. Nat. Commun. 2017, 8, 14505. [CrossRef] [PubMed]
30. Pucadyil, T.J.; Chattopadhyay, A. Cholesterol modulates ligand binding and G-protein coupling to
serotonin(1A) receptors from bovine hippocampus. Biochim. Biophys. Acta 2004, 1663, 188–200. [CrossRef]
[PubMed]
31. Klein, U.; Gimpl, G.; Fahrenholz, F. Alteration of the myometrial plasma membrane cholesterol content with
beta.-cyclodextrin modulates the binding affinity of the oxytocin receptor. Biochemistry 1995, 34, 13784–13793.
[CrossRef] [PubMed]
32. Nguyen, D.H.; Taub, D. CXCR4 function requires membrane cholesterol: Implications for HIV infection.
J. Immunol. 2002, 168, 4121–4126. [CrossRef] [PubMed]
33. Schrödinger, M. LLC New York, NY: 2009. Available online: https://www.schrodinger.com (accessed on
8 October 2018).
34. Baker, N.A.; Sept, D.; Joseph, S.; Holst, M.J.; McCammon, J.A. Electrostatics of nanosystems: Application to
microtubules and the ribosome. Proc. Natl. Acad. Sci. USA 2001, 98, 10037–10041. [CrossRef] [PubMed]
35. Batyuk, A.; Galli, L.; Ishchenko, A.; Han, G.W.; Gati, C.; Popov, P.A.; Lee, M.Y.; Stauch, B.; White, T.A.;
Barty, A.; et al. Native phasing of X-ray free-electron laser data for a G protein-coupled receptor. Sci. Adv.
2016, 2, e1600292. [CrossRef] [PubMed]
36. Martin-Garcia, J.M.; Conrad, C.E.; Nelson, G.; Stander, N.; Zatsepin, N.A.; Zook, J.; Zhu, L.; Geiger, J.;
Chun, E.; Kissick, D.; et al. Serial millisecond crystallography of membrane and soluble protein microcrystals
using synchrotron radiation. IUCrJ 2017, 4, 439–454. [CrossRef] [PubMed]
37. Melnikov, I.; Polovinkin, V.; Kovalev, K.; Gushchin, I.; Shevtsov, M.; Shevchenko, V.; Mishin, A.; Alekseev, A.;
Rodriguez-Valera, F.; Borshchevskiy, V.; et al. Fast iodide-SAD phasing for high-throughput membrane
protein structure determination. Sci. Adv. 2017, 3, e1602952. [CrossRef] [PubMed]
Molecules 2018, 23, 2616 15 of 17
38. Broecker, J.; Morizumi, T.; Ou, W.L.; Klingel, V.; Kuo, A.; Kissick, D.J.; Ishchenko, A.; Lee, M.Y.; Xu, S.;
Makarov, O.; et al. High-throughput in situ X-ray screening of and data collection from protein crystals at
room temperature and under cryogenic conditions. Nat. Protoc. 2018, 13, 260–292. [CrossRef] [PubMed]
39. Eddy, M.T.; Lee, M.-Y.; Gao, Z.-G.; White, K.L.; Didenko, T.; Horst, R.; Audet, M.; Stanczak, P.; McClary, K.M.;
Han, G.W.; et al. Allosteric coupling of drug binding and intracellular signaling in the A2A adenosine
receptor. Cell 2018, 172, 68–80.e12. [CrossRef] [PubMed]
40. Weinert, T.; Olieric, N.; Cheng, R.; Brunle, S.; James, D.; Ozerov, D.; Gashi, D.; Vera, L.; Marsh, M.; Jaeger, K.;
et al. Serial millisecond crystallography for routine room-temperature structure determination at synchrotrons.
Nat. Commun. 2017, 8, 542. [CrossRef] [PubMed]
41. Kim, J.; Jiang, Q.; Glashofer, M.; Yehle, S.; Wess, J.; Jacobson, K.A. Glutamate residues in the second
extracellular loop of the human A2a adenosine receptor are required for ligand recognition. Mol. Pharmacol.
1996, 49, 683–691. [PubMed]
42. Sun, B.; Bachhawat, P.; Chu, M.L.; Wood, M.; Ceska, T.; Sands, Z.A.; Mercier, J.; Lebon, F.; Kobilka, T.S.;
Kobilka, B.K. Crystal structure of the adenosine A2A receptor bound to an antagonist reveals a potential
allosteric pocket. Proc. Natl. Acad. Sci. USA 2017, 114, 2066–2071. [CrossRef] [PubMed]
43. Jaakola, V.-P.; Lane, J.R.; Lin, J.Y.; Katritch, V.; IJzerman, A.P.; Stevens, R.C. Identification and characterization
of amino acid residues essential for human A2A adenosine receptor: ZM241385 binding and subtype
selectivity. J. Biol. Chem. 2010, 285, 13032–13044. [CrossRef] [PubMed]
44. Allende, M.L.; Dreier, J.L.; Mandala, S.; Proia, R.L. Expression of the sphingosine 1-phosphate receptor, S1P1,
on T-cells controls thymic emigration. J. Biol. Chem. 2004, 279, 15396–15401. [CrossRef] [PubMed]
45. Wagner, J.R.; Lee, C.T.; Durrant, J.D.; Malmstrom, R.D.; Feher, V.A.; Amaro, R.E. Emerging computational
methods for the rational discovery of allosteric drugs. Chem. Rev. 2016, 116, 6370–6390. [CrossRef] [PubMed]
46. Baker, F.N.; Porollo, A. CoeViz: A web-based tool for coevolution analysis of protein residues. BMC Bioinform.
2016, 17, 119. [CrossRef] [PubMed]
47. Burger, L.; van Nimwegen, E. Disentangling direct from indirect co-evolution of residues in protein
alignments. PLoS Comput. Biol. 2010, 6, e1000633. [CrossRef] [PubMed]
48. De Juan, D.; Pazos, F.; Valencia, A. Emerging methods in protein co-evolution. Nat. Rev. Genet. 2013, 14,
249–261. [CrossRef] [PubMed]
49. Pang, X.; Yang, M.; Han, K. Antagonist binding and induced conformational dynamics of GPCR A2A
adenosine receptor. Proteins 2013, 81, 1399–1410. [CrossRef] [PubMed]
50. Lee, J.Y.; Lyman, E. Agonist dynamics and conformational selection during microsecond simulations of the
A(2A) adenosine receptor. Biophys. J. 2012, 102, 2114–2120. [CrossRef] [PubMed]
51. Seddon, A.M.; Curnow, P.; Booth, P.J. Membrane proteins, lipids and detergents: Not just a soap opera.
Biochim. Biophys. Acta Biomembr. 2004, 1666, 105–117. [CrossRef] [PubMed]
52. Wacker, D.; Fenalti, G.; Brown, M.A.; Katritch, V.; Abagyan, R.; Cherezov, V.; Stevens, R.C. Conserved binding
mode of human beta2 adrenergic receptor inverse agonists and antagonist revealed by X-ray crystallography.
J. Am. Chem. Soc. 2010, 132, 11443–11445. [CrossRef] [PubMed]
53. Naranjo, A.N.; Chevalier, A.; Cousins, G.D.; Ayettey, E.; McCusker, E.C.; Wenk, C.; Robinson, A.S. Conserved
disulfide bond is not essential for the adenosine A2A receptor: Extracellular cysteines influence receptor
distribution within the cell and ligand-binding recognition. Biochim. Biophys. Acta 2015, 1848, 603–614.
[CrossRef] [PubMed]
54. Chattopadhyay, A. GPCRs: Lipid-dependent membrane receptors that act as drug targets. Adv. Biol. 2014,
2014, 1–12. [CrossRef]
55. Dijkman, P.M.; Watts, A. Lipid modulation of early G protein-coupled receptor signalling events.
Biochim. Biophys. Acta 2015, 1848, 2889–2897. [CrossRef] [PubMed]
56. Hurst, D.P.; Grossfield, A.; Lynch, D.L.; Feller, S.; Romo, T.D.; Gawrisch, K.; Pitman, M.C.; Reggio, P.H.
A Lipid pathway for ligand binding is necessary for a cannabinoid G protein-coupled receptor. J. Biol. Chem.
2010, 285, 17954–17964. [CrossRef] [PubMed]
57. Olanow, C.W. Oxidation reactions in Parkinson’s disease. Neurology 1990, 40, 37–39.
58. Ikeda, K.; Kurokawa, M.; Aoyama, S.; Kuwana, Y. Neuroprotection by adenosine A2A receptor blockade in
experimental models of Parkinson’s disease. J. Neurochem. 2002, 80, 262–270. [CrossRef] [PubMed]
Molecules 2018, 23, 2616 16 of 17
59. Sung, Y.M.; Wilkins, A.D.; Rodriguez, G.J.; Wensel, T.G.; Lichtarge, O. Intramolecular allosteric
communication in dopamine D2 receptor revealed by evolutionary amino acid covariation. Proc. Natl.
Acad. Sci. USA 2016, 113, 3539–3544. [CrossRef] [PubMed]
60. Canals, M.; Burgueno, J.; Marcellino, D.; Cabello, N.; Canela, E.I.; Mallol, J.; Agnati, L.; Ferre, S.; Bouvier, M.;
Fuxe, K.; et al. Homodimerization of adenosine A2A receptors: Qualitative and quantitative assessment by
fluorescence and bioluminescence energy transfer. J. Neurochem. 2004, 88, 726–734. [CrossRef] [PubMed]
61. Franco, R.; Martinez-Pinilla, E.; Lanciego, J.L.; Navarro, G. Basic pharmacological and structural evidence
for class A G-protein-coupled receptor heteromerization. Front. Pharmacol. 2016, 7, 76. [CrossRef] [PubMed]
62. Fanelli, F.; Felline, A. Dimerization and ligand binding affect the structure network of A2A adenosine
receptor. Biochim. Biophys. Acta Biomembr. 2011, 1808, 1256–1266. [CrossRef] [PubMed]
63. Matsunaga, Y.; Komuro, Y.; Kobayashi, C.; Jung, J.; Mori, T.; Sugita, Y. Dimensionality of collective variables
for describing conformational changes of a multi-domain protein. J. Phys. Chem. Lett. 2016, 7, 1446–1451.
[CrossRef] [PubMed]
64. Gilson, M.K.; Zhou, H.X. Calculation of protein-ligand binding affinities. Annu. Rev. Biophys. Biomol. Struct.
2007, 36, 21–42. [CrossRef] [PubMed]
65. Jafurulla, M.; Chattopadhyay, A. Sphingolipids in the function of G protein-coupled receptors. Eur. J.
Pharmacol. 2015, 763, 241–246. [CrossRef] [PubMed]
66. Massink, A.; Gutierrez-de-Teran, H.; Lenselink, E.B.; Ortiz Zacarias, N.V.; Xia, L.; Heitman, L.H.; Katritch, V.;
Stevens, R.C.; AP, I.J. Sodium ion binding pocket mutations and adenosine A2A receptor function.
Mol. Pharmacol. 2015, 87, 305–313. [CrossRef] [PubMed]
67. Pfrieger, F.W. Role of cholesterol in synapse formation and function. Biochim. Biophys. Acta 2003, 1610,
271–280. [CrossRef]
68. Serebryany, E.; Zhu, G.A.; Yan, E.C. Artificial membrane-like environments for in vitro studies of purified
G-protein coupled receptors. Biochim. Biophys. Acta 2012, 1818, 225–233. [CrossRef] [PubMed]
69. Andreoli, T.E.; Hoffman, J.F.; Fanestil, D.D. Membrane Physiology; Springer: Boston, MA, USA, 1980.
70. DeLano, W.L. The PyMol Molecular Graphics System; DeLano Scientific LLC: San Carlos, CA, USA, 2002.
71. Dolinsky, T.J.; Czodrowski, P.; Li, H.; Nielsen, J.E.; Jensen, J.H.; Klebe, G.; Baker, N.A. PDB2PQR: Expanding
and upgrading automated preparation of biomolecular structures for molecular simulations. Nucleic Acids
Res. 2007, 35, W522–W525. [CrossRef] [PubMed]
72. Best, R.B.; Hummer, G. Optimized molecular dynamics force fields applied to the helix-coil transition of
polypeptides. J. Phys. Chem. B 2009, 113, 9004–9015. [CrossRef] [PubMed]
73. Jambeck, J.P.; Lyubartsev, A.P. Derivation and systematic validation of a refined all-atom force field for
phosphatidylcholine lipids. J. Phys. Chem. B 2012, 116, 3164–3179. [CrossRef] [PubMed]
74. Jambeck, J.P.; Lyubartsev, A.P. An extension and further validation of an all-atomistic force field for biological
membranes. J. Chem. Theory Comput. 2012, 8, 2938–2948. [CrossRef] [PubMed]
75. Jorgensen, W.L.; Chandrasekhar, J.; Madura, J.D.; Impey, R.W.; Klein, M.L. Comparison of simple potential
functions for simulating liquid water. J. Chem. Phys. 1983, 79, 926–935. [CrossRef]
76. Wang, J.; Wolf, R.M.; Caldwell, J.W.; Kollman, P.A.; Case, D.A. Development and testing of a general amber
force field. J. Comput. Chem. 2004, 25, 1157–1174. [CrossRef] [PubMed]
77. Frisch, M.J.; Trucks, G.W.; Schlegel, H.B.; Scuseria, G.E.; Robb, M.A.; Cheeseman, J.R.; Scalmani, G.; Barone, V.;
Mennucci, B.; Petersson, G.A.; et al. Gaussian 09, Revision A.02; Gaussian Inc.: Wallingford, CT, USA, 2009.
78. Wang, J.; Cieplak, P.; Kollman, P.A. How well does a restrained electrostatic potential (RESP) model perform
in calculating conformational energies of organic and biological molecules? J. Comput. Chem. 2000, 21,
1049–1074. [CrossRef]
79. Case, D.A.; Cheatham, T.E., III; Darden, T.; Gohlke, H.; Luo, R.; Merz, K.M., Jr.; Onufriev, A.; Simmerling, C.;
Wang, B.; Woods, R.J. The amber biomolecular simulation programs. J. Comput. Chem. 2005, 26, 1668–1688.
[CrossRef] [PubMed]
80. Van Der Spoel, D.; Lindahl, E.; Hess, B.; Groenhof, G.; Mark, A.E.; Berendsen, H.J. GROMACS: Fast, flexible,
and free. J. Comput. Chem. 2005, 26, 1701–1718. [CrossRef] [PubMed]
81. Hünenberger, P. Thermostat algorithms for molecular dynamics simulations. Adv. Comput. Simul. 2005,
105–149. [CrossRef]
82. Parrinello, M.; Rahman, A. Polymorphic transitions in single-crystals—A new molecular-dynamics method.
J. Appl. Phys. 1981, 52, 7182–7190. [CrossRef]
Molecules 2018, 23, 2616 17 of 17
83. Darden, T.; York, D.; Pedersen, L. Particle mesh ewald—An N.Log(N) method for ewald sums in large
systems. J. Chem. Phys. 1993, 98, 10089–10092. [CrossRef]
84. Hess, B.; Bekker, H.; Berendsen, H.J.C.; Fraaije, J.G.E.M. LINCS: A linear constraint solver for molecular
simulations. J. Comput. Chem. 1997, 18, 1463–1472. [CrossRef]
85. Bonomi, M.; Branduardi, D.; Bussi, G.; Camilloni, C.; Provasi, D.; Raiteri, P.; Donadio, D.; Marinelli, F.;
Pietrucci, F.; Broglia, R.A.; et al. PLUMED: A portable plugin for free-energy calculations with molecular
dynamics. Comput. Phys. Commun. 2009, 180, 1961–1972. [CrossRef]
86. Bochicchio, A.; Rossetti, G.; Tabarrini, O.; Kraubeta, S.; Carloni, P. Molecular view of ligands specificity for
CAG repeats in anti-Huntington therapy. J. Chem. Theory Comput. 2015, 11, 4911–4922. [CrossRef] [PubMed]
87. Nguyen, T.H.; Rossetti, G.; Arnesano, F.; Ippoliti, E.; Natile, G.; Carloni, P. Molecular recognition of platinated
DNA from chromosomal HMGB1. J. Chem. Theory Comput. 2014, 10, 3578–3584. [CrossRef] [PubMed]
88. Kranjc, A.; Bongarzone, S.; Rossetti, G.; Biarnes, X.; Cavalli, A.; Bolognesi, M.L.; Roberti, M.; Legname, G.;
Carloni, P. Docking ligands on protein surfaces: The case study of prion protein. J. Chem. Theory Comput.
2009, 5, 2565–2573. [CrossRef] [PubMed]
89. Paramo, T.; East, A.; Garzon, D.; Ulmschneider, M.B.; Bond, P.J. Efficient characterization of protein cavities
within molecular simulation trajectories: Trj_cavity. J. Chem. Theory Comput. 2014, 10, 2151–2164. [CrossRef]
[PubMed]
90. Humphrey, W.; Dalke, A.; Schulten, K. VMD: Visual molecular dynamics. J. Mol. Graph. 1996, 14, 33–38.
[CrossRef]
91. Porollo, A.A.; Adamczak, R.; Meller, J. POLYVIEW: A flexible visualization tool for structural and functional
annotations of proteins. Bioinformatics 2004, 20, 2460–2462. [CrossRef] [PubMed]
92. Klotz, K.-N.; Hessling, J.; Hegler, J.; Owman, C.; Kull, B.; Fredholm, B.; Lohse, M. Comparative pharmacology
of human adenosine receptor subtypes–characterization of stably transfected receptors in CHO cells.
Naunyn-Schmiedeberg’s Arch. Pharmacol. 1997, 357, 1–9. [CrossRef]
93. Neuhoff, V.; Philipp, K.; Zimmer, H.G.; Mesecke, S. A Simple, Versatile, Sensitive and Volume-Independent
Method for Quantitative Protein Determination which is Independent of Other External Influences.
Biol. Chem. 1979, 360, 1657–1670. [CrossRef]
94. Stevens, R.C.; Cherezov, V.; Katritch, V.; Abagyan, R.; Kuhn, P.; Rosen, H.; Wuthrich, K. The GPCR network:
A large-scale collaboration to determine human GPCR structure and function. Nat. Rev. Drug Discov. 2013,
12, 25–34. [CrossRef] [PubMed]
95. Pietrucci, F.; Marinelli, F.; Carloni, P.; Laio, A. Substrate binding mechanism of HIV-1 protease from
explicit-solvent atomistic simulations. J. Am. Chem. Soc. 2009, 131, 11811–11818. [CrossRef] [PubMed]
© 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC BY) license (http://creativecommons.org/licenses/by/4.0/).
